J 2022

Combinatorial pathway disruption is a powerful approach to delineate metabolic impacts of endocrine disruptors

BERNAL, Kevin, Charbel TOUMA, Chedi ERRADHOUANI, Talia BORONAT-BELDA, Lucas GAILLARD et. al.

Basic information

Original name

Combinatorial pathway disruption is a powerful approach to delineate metabolic impacts of endocrine disruptors

Authors

BERNAL, Kevin, Charbel TOUMA, Chedi ERRADHOUANI, Talia BORONAT-BELDA, Lucas GAILLARD, Sara AL KASSIR, Helene LE MENTEC, Corinne MARTIN-CHOULY, Normand PODECHARD, Dominique LAGADIC-GOSSMANN, Sophie LANGOUET, Francois BRION, Anja KNOLL-GELLIDA, Patrick J. BABIN, Iva SOVADINOVÁ (203 Czech Republic, belonging to the institution), Pavel BABICA (203 Czech Republic, guarantor, belonging to the institution), Karine ANDREAU, Robert BAROUKI (250 France), Jan VONDRACEK, Paloma ALONSO-MAGDALENA, Etienne BLANC, Min Ji KIM and Xavier COUMOUL

Edition

FEBS Letters, Hoboken, Wiley, 2022, 0014-5793

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

RIV identification code

RIV/00216224:14310/22:00127970

Organization

Přírodovědecká fakulta – Repository – Repository

UT WoS

000842558900001

EID Scopus

2-s2.0-85136484940

Keywords in English

appetite; bisphenol; dioxin; inflammation; insulin resistance; microbiota; perfluorinated compounds; phthalate; TBT

Links

EF17_043/0009632, research and development project. 825712, interní kód Repo. 857560, interní kód Repo. RECETOX RI, large research infrastructures.
Changed: 14/6/2025 00:50, RNDr. Daniel Jakubík

Abstract

V originále

The prevalence of metabolic diseases, such as obesity, diabetes, metabolic syndrome and chronic liver diseases among others, has been rising for several years. Epidemiology and mechanistic (in vivo, in vitro and in silico) toxicology have recently provided compelling evidence implicating the chemical environment in the pathogenesis of these diseases. In this review, we will describe the biological processes that contribute to the development of metabolic diseases targeted by metabolic disruptors, and will propose an integrated pathophysiological vision of their effects on several organs. With regard to these pathomechanisms, we will discuss the needs, and the stakes of evolving the testing and assessment of endocrine disruptors to improve the prevention and management of metabolic diseases that have become a global epidemic since the end of last century.

Files attached